You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Therapy Areas: Oncology
AstraZeneca secures US approval for Imfinzi–BCG regimen in high‑risk bladder cancer
Login
Username:

Password:


Related Headlines

Orsini to chosen as contracted specialty pharmacy for Gilead's Hepcludex (bulevirtide-gmod)

OncoZenge secures European approval for Phase III BEAM-Pain trial of BupiZenge

Transgene to present preclinical TG-MVA mpox vaccine data at World Congress on Infectious Diseases

Pierre Fabre Laboratories' BRAFTOVI (encorafenib) combination receives CHMP positive opinion in BRAFV600E-mutant mCRC

Menarini Group to present new elacestrant and tagraxofusp data at ASCO 2026 Annual Meeting

Enhertu recommended for EU approval in previously treated HER2 positive metastatic solid tumours

OSE Immunotherapeutics reports positive Phase 2 ovarian cancer trial results

Whitehawk Therapeutics signs new option agreement for use of CPT113 linker-payload

4basebio secures clinical supply agreement for Phase II immunotherapy trial

FDA approves MEKanistic Therapeutics' IND for MTX-531

Matter Bio submits first IND application for Lm-LLO-TT

Myosin Therapeutics doses first patient in Phase 1/2 study of MT-125 in GBM

Nanjing Leads Biolabs receives Chinese approval for pivotal Phase III trial of PD-L1/4-1BB bispecific antibody

ImmunityBio secures US patent portfolio covering ANKTIVA combination therapy through to 2035

CelLBxHealth partners with AdventHealth on cancer monitoring studies

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026